Poussot to take over as Wyeth CEO

Share this article:

Wyeth will promote its No. 2 executive, Bernard Poussot, to CEO effective Jan.1 under a planned succession, the drugmaker said.

Poussot will succeed current CEO Robert Essner, who will become non-executive chairman of the board during a transition period beginning in the new year.

Poussot has served as Wyeth's president and vice chairman since April 2006. In January he added the role of chief operating officer.

Essner has worked at Wyeth since 1989 and has been CEO since May 2001.
 

Share this article:
close

Next Article in News

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.